Regencell Bioscience Holdings Limited
RGC · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 136.35 | 0.36 | 2.47 | -0.14 |
| FCF Yield | -0.04% | -9.59% | -1.66% | -1.34% |
| EV / EBITDA | -2,639.60 | -10.75 | -56.44 | -63.60 |
| Quality | ||||
| ROIC | -69.75% | -57.04% | -50.38% | -41.71% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.92 | 0.85 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 18.49% | 19.70% | 17.49% | -688.20% |
| Safety | ||||
| Net Debt / EBITDA | 0.59 | 0.79 | 0.21 | 0.81 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -13.61 | -21.90 |
| Cash Conversion Cycle | 0.00 | 0.00 | -26.82 | -16.67 |